VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Verastem reported positive preliminary data from the TARGET-D 101 Phase 1/2 trial of VS-7375, showing anti-tumor activity and a favorable safety profile in KRAS G12D-mutated solid tumors. In heavily pretreated metastatic pancreatic cancer patients, 93% (13/14) achieved a greater than 50% reduction in the CA19-9 tumor marker at the 900 mg dose, with low-grade gastrointestinal adverse events attenuating after the first cycle.
Key figures
- Drug Name
- VS-7375
- Phase Of Trial
- Phase 1/2
- Data cutoff
- June 12, 2026
- Target dose mg
- 900 mg QD
- Ca19 9 response n
- 13/14
- Ca19 9 response rate
- 93%
- Current dose escalation mg
- 1200 mg QD
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.